Skeletal Plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database

Previous reports suggest an as yet unidentifiable subset of patients with plasmacytoma will progress to myeloma. The current study sought to establish the risk of developing myeloma and determine the prognostic factors affecting the progression of disease. Patients with plasmacytoma diagnosed betwee...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2009-09, Vol.2 (1), p.41-41, Article 41
Main Authors: Jawad, Muhammad Umar, Scully, Sean P
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Bone Neoplasms - mortality
Bone Neoplasms - pathology
Bone Neoplasms - therapy
Child
Child, Preschool
Databases, Factual
Disease Progression
Humans
Infant
Infant, Newborn
Middle Aged
Orthopedics - methods
Plasmacytoma - mortality
Plasmacytoma - pathology
Plasmacytoma - therapy
Radiotherapy - methods
Retrospective Studies
SEER Program
Survival Analysis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous reports suggest an as yet unidentifiable subset of patients with plasmacytoma will progress to myeloma. The current study sought to establish the risk of developing myeloma and determine the prognostic factors affecting the progression of disease. Patients with plasmacytoma diagnosed between 1973 and 2005 were identified in the SEER database(1164 patients). Patient demographics and clinical characteristics, treatment(s), cause of death, and survival were extracted. Kaplan-Meier, log-rank, and Cox regression were used to analyze prognostic factors. The five year survival among patients initially diagnosed with plasmacytoma that later progressed to multiple myeloma and those initially diagnosed with multiple myeloma were almost identical (25% and 23%; respectively). Five year survival for patients with plasmacytoma that did not progress to multiple myeloma was significantly better (72%). Age > 60 years was the only factor that correlated with progression of disease (p = 0.027). Plasmacytoma consists of two cohorts of patients with different overall survival; those patients that do not progress to systemic disease and those that develop myeloma. Age > 60 years is associated with disease progression. Identifying patients with systemic disease early in the treatment will permit aggressive and novel treatment strategies to be implemented.
ISSN:1756-8722
1756-8722
DOI:10.1186/1756-8722-2-41